PharmenaWAR:PHR +2.92%56 Forward Dividend Yield % is 76.62% as of Jun. 30, 2026. GuruFocus rates WAR:PHR with a GF Score™ of 56/100 and a GF Value™ of zł5.78 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 145 Biotechnology companies, Pharmena ranks better than 99.31% on this metric.
As of today (2026-06-30), the Forward Annual Dividend Yield of Pharmena is 76.62%.
As of today (2026-06-30), the Trailing Annual Dividend Yield of Pharmena is 0.00%.
WAR:PHR's Forward Dividend Yield % is ranked better than 99.31% of 145
companies
in the Biotechnology industry
Industry Median: 1.52
vs WAR:PHR: 76.62
During the past 12 months, Pharmena's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Pharmena was 146.60% per year. The lowest was 6.20% per year. And the median was 26.85% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
WAR:PHR vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Pharmena's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmena Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmena's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Pharmena's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 76.62% mean?
Pharmena (WAR:PHR) has a Forward Dividend Yield % of 76.62% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pharmena and its competitors. According to the industry distribution chart, Pharmena ranks #1 out of 145 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Pharmena's Forward Dividend Yield % too high?
Pharmena's current Forward Dividend Yield % is 76.62%. The Biotechnology industry median Forward Dividend Yield % is 1.52. Pharmena's value of 76.62% is 4940.8% above this industry median. Based on the distribution chart, Pharmena ranks #1 out of 145 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmena has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmena's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmena ranks #1 out of 145 companies for Forward Dividend Yield %. This places Pharmena in the top 1% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 1.52. Pharmena's value of 76.62% is 4940.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.52, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmena's current Forward Dividend Yield % of 76.62% is 4940.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pharmena and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmena's current Forward Dividend Yield % is 76.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmena stock overvalued right now?
Based on GuruFocus' analysis, Pharmena (WAR:PHR) is currently considered Possible Value Trap. The stock's GF Value™ is zł5.78, compared to a current price of zł3.17 — trading 45.2% below its estimated fair value. The current Forward Dividend Yield % is 76.62% and 4940.8% above the Biotechnology industry median of 1.52. Pharmena's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Pharmena (WAR:PHR), the current Forward Dividend Yield % is 76.62% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmena (WAR:PHR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmena stock appears to be undervalued.
The current stock price of zł3.17 is trading 45.2% below its estimated GF Value™ of zł5.78.
GuruFocus considers Pharmena to be Possible Value Trap.
Key valuation signals for WAR:PHR:
Forward Dividend Yield %: 76.62%
GF Value™: zł5.78 vs. price of zł3.17 (45.2% below fair value)
Industry Position: 4940.8% above the Biotechnology median (#1 of 145)
No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
56GF Score
Get the complete analysis for WAR:PHR
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:PHR has been successfully added to your 